A B S T R A C T Plasma immunoreactive glucagon (IRG) concentrations were measured in 36 patients with chronic renal failure (CRF) and 32 normal subjects. In addition, the components of circulating IRG were analyzed by gel filtration in the fasting state and after physiological stimuli. Fasting IRG was elevated (P< 0.001) in CRF patients (534±32 pg/ml) compared with the levels found in healthy subjects (113±9 pg/ ml). Oral glucose suppressed plasma IRG in CRF patients from a basal level of 568+52 to a nadir of 354± 57 pg/ml (120 min). This degree of suppression (38%) was comparable to that found in normal subjects (basal = 154±20 to 100±23 pg/ml) at 120 min (35%). Intravenous infusion of arginine (250 mg/kg) resulted in a 71% rise in IRG in CRF patients and a 166% increase in normal subjects.
A B S T R A C T Plasma immunoreactive glucagon (IRG) concentrations were measured in 36 patients with chronic renal failure (CRF) and 32 normal subjects. In addition, the components of circulating IRG were analyzed by gel filtration in the fasting state and after physiological stimuli. Fasting IRG was elevated (P< 0.001) in CRF patients (534±32 pg/ml) compared with the levels found in healthy subjects (113±9 pg/ ml). Oral glucose suppressed plasma IRG in CRF patients from a basal level of 568+52 to a nadir of 354± 57 pg/ml (120 min). This degree of suppression (38%) was comparable to that found in normal subjects (basal = 154±20 to 100±23 pg/ml) at 120 min (35%). Intravenous infusion of arginine (250 mg/kg) resulted in a 71% rise in IRG in CRF patients and a 166% increase in normal subjects.
Gel filtration of fasting plasma from CRF patients showed three major peaks. The earliest (A) was found in the void volume (mol wt> 40,000) and constituted 16 .5±4.7% of the elution profile. The middle peak (B) eluted just beyond the proinsulin marker (approximately 9,000 mol wt) and constituted the largest proportion of the elution profile (56.5±3.4%). The Received for publication 25 February 1976 and in revised form 19 April 1976. glucose, glucagon immunoreactivity in the 3,500 mol wt peak (C) was markedly suppressed, while the B peak in patients with CRF declined to a lesser extent. The A peak in both groups was unchanged. After an arginine infusion only the C peak increased in both groups of subjects.
Gel filtration of plasma in 3 M acetic acid gave similar profiles to those obtained in glycine albumin buffer. Exposure of serum to trypsin indicated that the B and C peaks were digestible, while the A peak was resistant to the action of the enzyme. In one sample, peak C increased after a 2-h exposure of serum to trypsin.
We conclude that circulating IRG in normal subjects and patients with CRF is heterogenous. The hyperglucagonemia of renal failure is largely due to an increase in IRG material of approximately 9,000 mol wt, consistent with proglucagon, although the 3,500 mol wt component is also considerably elevated (threefold).
INTRODUCTION
Chronic renal failure (CRF) 1 is accompanied by elevated plasma immunoreactive glucagon (IRG) levels (1) (2) (3) (4) (5) (6) . In a preliminary communication (7) we have shown that circulating IRG in this condition is heterogenous, and that a significant amount of glucagon immunoreactivity is present in a peak with a molecular weight of approximately 9,000, consistent with descriptions of proglucagon (8) (9) (10) (11) (12) (13) (14) . Studies by other investigators have indicated that IRG may exist in several forms in plasma of normal and diabetic subjects (15, 16) and of experimental animals (17, 18) . However, the responses of the various plasma IRG species to physiological stimuli have not been defined in detail, and their significance is uncertain. Valverde et al. (16) showed that arginine stimulated only the IRG of 3,500 mol wt ("true" glucagon) in normal man. In another report (17) similar results were noted in pancreatectomized dogs. In addition these authors pointed out that an infusion of somatostatin caused a reduction of both the 3,500 and 9,000 mol wt material (17) . In Gel filtration. 1 or 2 ml plasma was gel-filtered on 50 x 1-cm Biogel P-30 columns (Bio-Rad Laboratories, Richmond, Calif.). The samples were eluted under gravity at room temperature with 0.2 M glycine buffer, pH 8.8, containing 0.25%o human serum albumin, lo lamb serum, and 500 U/ml Trasylol (FBA Pharmaceuticals, Inc., New York). 1-ml fractions were collected and the total volume assayed. For the acetic acid studies, 1.5 ml plasma was gel filtered on 58 X 2-cm Biogel P-30 columns and eluted with 3 M acetic acid. 3-ml fractions were collected and evaporated in vacuo, reconstituted in 1.0 ml glycine buffer and assayed. The columns were callibrated using 'I-y-globulin, porcine proinsulin (9,033 mol wt), porcine insulin (5,777 mol wt), glucagon (3,485 mol wt), or 'I-glucagon, and 1I-Na.
Trypsin digestion. Tryptic hydrolysis was carried out as follows: 1.0 ml CRF plasma (three samples) was incubated with diphenyl carbamyl chloride-treated trypsin at an enzyme protein ratio 1: 100 for 2 and 6 h at room temperature with gentle mixing. The reaction was stopped by cooling and the addition of soybean trypsin inhibitor at an inhibitor/ trypsin ratio of 2: 1. Control and trypsin-treated samples were then gel filtered on Biogel P-30 columns. Pooled eluates from the 9,000 mol wt zone of a gel filtered CRF plasma sample were also subjected to tryptic hydrolysis and rechromatographed as described above.
Rat studies. In an attempt to reproduce the hyperglucagonemia of renal failure and to study its gel filtration characteristics, bilateral nephrectomy was carried out in six rats. Six other rats were sham operated (renal decapsulation). Both groups of animals remained fasting after the operative procedure. 24-48 h postoperatively, blood was collected by aortic puncture. Plasma samples were asssayed for IRG and analyzed by gel filtration as described above.
Statistical methods. Results are presented as means± SEM. The statistical significance of changes in individual subjects was assessed by analysis of paired differences and that of differences between group means by the Student's t test. P values less than 0.05 were considered significant. RESULTS Fasting IRG levels. The mean plasma IRG level in the CRF patients was 534+32 pg/ml (range 230-1,050 pg/ml). This was significantly higher (P < 0.001) than the concentration in the healthy subjects (113+9 pg/ ml). In only 3 of the 36 CRF patients, the plasma IRG level fell within the normal range of 40-266 pg/ml.
Glucose and IRG responses to oral glucose and arginine infusion. Plasma IRG and glucose responses to oral glucose are shown in Fig. 1 . In the CRF patients the mean fasting plasma IRG (568±52 pg/ml) was suppressed by 38% to 354+57 pg/ml at the nadir (120 min). A similar degree of suppression of IRG (35%) was found in normal subjects, i.e., 154+20 pg/ml fasting to 100+23 pg/ml at 120 min. Glucose tolerance in the renal failure patients was less than in the normal controls. The were found in normal samples with low concentrations of total IRG. The recovery of known amounts of purified beef-pork glucagon dissolved in buffer was 95%, which was similar to the result obtained when the same standard was added to plasma and then gel filtered. Both elution profiles were comparable. Aliquots of a pooled plasma sample run twice on the same column and on different columns gave essentially similar profiles.
Representative gel filtration profiles of plasma samples from fasting CRF and normal subjects are shown in Figs. 3 and 4 , respectively. In the CRF patients (10 samples), three major peaks were detected (Tables I  and II ). The earliest peak (A) was found in the void volume (mol wt > 40,000) and constituted 16.5±4.7 of the eluted IRG. The second peak (B) eluted in the region of the proinsulin marker (9,000 mol wt) and represented the largest proportion of the elution profile (56.5±3.4%). The eluting in peak C (27 and 46% in CRF and normal subjects, respectively) were arbitrarily used to estimate the true glucagon level in all subjects studied, the mean values in the 36 CRF patients (144 pg/ml) would still be considerably higher than in the 32 controls (52 pg/ml ).
The elution profiles of plasma samples from CRF patients and normal subjects after glucose administration are shown in Fig. 3 , and the distribution of glucagon immunoreactivity in the various peaks is shown in Table I . IRG in peak A was similar at both sampling times in the two groups of subjects. In contrast, IRG in peak C was significantly suppressed by oral glucose (P < 0.05), while in the CRF patients a small decline in peak B material also occurred, which bordered on statistical significance (0.1 > P > 0.05).
The elution profiles of plasma IRG before and after an arginine infusion are shown in Fig. 4 , and the distribution of IRG in peaks A, B, and C is shown in Table II . Only peak C changed significantly (P = < 0.05) in both groups of subjects.
Acetic acid studies. Gel filtration of CRF plasma samples on Biogel P-30 columns equilibrated in 3 M acetic acid resulted in IRG profiles similar to those Heterogeneity of Circulating Glucagon Representative elution profile of plasma IRG on 1 X 50-cm Biogel P-30 columns before and after arginine infusion in a patient with CRF (left) and in a healthy subject (right). The arginine was infused over 30 min at a dose of 250 mg/kg in the CRF patient and 500 mg/kg in the healthy subject found when the samples were eluted with glycine buffer trypsin for 2 and 6 h (Figs. 6 and 7) . In all three (Fig. 5) .
plasmas (the results of the third plasma were essenTrypsin studies. The elution profiles of plasma tially similar to those shown in Fig. 6 ), peak A insamples were examined before and after incubation with creased slightly at 2 h and been declined, but not to basal levels, at 6 h: Peak B completely disappeared by 6 h. In one subject, peak C increased substantially at 2 h and remained elevated at 6 h ( Fig. 7) , while in '25"I-y-lobulin Proinsulin Insulin '"5I-Glucagon 2 and 6 h after trypsin digestion. the other two subjects peak C diminished with the appearance of an additional, smaller molecular weight peak. The recovery of total IRG at 2 h approximated that of the control sample in all three experiments, but by 6 h only about 50% of the IRG was recoverable. As shown in Fig. 8 , repeat gel filtration of pooled eluates from the peak B region of a CRF patient showed a single peak in the expected zone. After exposure to trypsin for 30 min, IRG material in peak B was converted to substances eluting in the true glucagon and smaller molecular weight zones. The recovery after 30 min trypsin digestion was 80%.
Rat studies. Plasma IRG in the sham-operated rats was 119±12 pg/ml, while in the nephrectomized rats the values rose to 870±146 pg/ml. Gel filtration of plasma samples at 48 h (Fig. 9) showed that peak B was only present in the nephrectomized rats. 
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ported by Sherwin et (17) , who studied plasma glucagon immunoreactivity in pancreatectomized dogs and showed that infusions of insulin and somatostatin completely suppressed the 3,500 mol wt plasma component and reduced the 9,000 mol wt material to a lesser extent. It thus seems probable that prolonged glucose and arginine infusions, or other stimuli, may modulate the secretion of the higher molecular weight components.
The nature of the high molecular weight components of plasma IRG is at present unresolved. That they are not simple aggregates of 3,500 mol wt glucagon noncovalently bound to plasma proteins is suggested by the similar profiles when samples were gel filtered in either glycine buffer, pH 8.8, or in 3 M acetic acid. The 9,000 mol wt material was digested by trypsin in the three plasma samples studied. In two samples a new substance with a molecular weight smaller than 3,500 was generated. This is similar to the finding of Rigopoulou et al. (8) , who found a similar substance after trypsin digestion of the 9,000 and 3,500 mol wt materials extracted from canine pancreas. Digestion of one of our samples, however, showed that the 9,000 mol wt material was converted to a material similar in size to true glucagon, suggesting that this material may be proglucagon. The reason why a fourth peak was not found in this sample, or why 3,500 mol wt glucagon was not detected in the other samples, may be related to differences in the rate of tryptic digestion of the glucagon components in each plasma. Peak A was resistant to trypsin and increased after exposure of plasma to the enzyme for 2 h. Valverde et al. (16) reported similar results in normal plasma. This increase might be due to immunoreactive fragments of glucagon, generated by trypsin, binding to plasma proteins. Another possible explanation is that the trypsin exposed new glucagon immunoreactive sites in this large molecule.
Of the three IRG peaks found in plasma, only the 3,500 mol wt IRG has been shown to be biologically active in studies carried out thus far. Rigopoulou et al. (8) reported that the 9,000 molv wt material in extracts of canine pancreas did not have glycogenolytic activity in the isolated perfused liver preparation. Therefore since both large molecular weight IRG components constitute a significant proportion of total plasma IRG in both normal subjects and CRF patients, caution must be exerted in the interpretation of the biological significance of plasma "glucagon" as measured by radioimmunoassay. This finding is also important in interpreting experiments concerned with the dynamics of plasma IRG, because the presence of high concentrations of immunologically cross-reacting material reduces the calculated magnitude of the response of true plasma glucagon to inhibitors or secretagogues. For instance, the rise in the 3,500 mol wt component after arginine in CRF patients is actually 322 and not 72%, which is the figure calculated from the total plasma IRG values. A further point that must be established concerns the relative immunoreactivity of the material in the A and B peaks compared to the 3,500 mol wt glucagon with different glucagon antisera. The experience with an analogous situation, i.e., proinsulin and insulin, suggests that a considerable variation in reactivity may be found and that these differences may account for the wide range of absolute concentrations for circulating IRG which have been reported. The findings of Bilbrey et al.
(1) are imlportant in this regard because these authors found that more than 80% of IRG in a single plasma from a patient with CRF eluted in the 3,500 mol wt zone when assayed with rabbit antiglucagon serum G58. Lesser reactivity of the 9,000 mol wt material with the G58 compared to the 30K antiserum may provide an explanation for the quantitative difference between their result and those in the present study. It should also be stressed that the values for the material in the A and B peaks have been expressed in terms of the 3,500 mol wt glucagon standard. If these components react less well with the 30K antiserum than the 3,500 mol wt glucagon standard, their absolute concentrations will be higher than those reported in this study. Resolution of this problem will necessarily require the availability of highly purified A and B components.
The 9,000 mol wt IRG in CRF plasma resembles material which is present in the pancreas of man and animals and which is now believed to be proglucagon (9) (10) (11) (12) (13) (14) . Our studies lend support to the possibility that this circulating material might be proglucagon because exposure to trypsin converted it to small molecular weight components, some of which were similar in size to the native hormone. However, other interpretations are possible, and further studies are now required to unequivocally establish its nature. In any event, plasma from CRF patients is a rich source of this material for further biological and chemical studies.
